Enanta Reports Positive Phase 2 Data For Zelicapavir In Paediatric RSV Study; Stock Up

(RTTNews) - Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology company, Monday announced positive topline results from the Phase 2 study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV). The company's shares were up more than 4 percent in pre-market.

Results from the study, which was conducted in two parts in pediatric patients with RSV aged 28 days to 36 months, showed that zelicapavir demonstrated a viral load decline of 1.2 log compared to placebo at day 5. Additionally, Zelicapavir was well-tolerated with a favorable safety profile.

Enanta stock had closed at $8.00, down 0.12 percent on Friday. It has traded in the range of $7.86 - $17.80 in the last 1 year.